BOSTON, July 21, 2015 /PRNewswire/ -- PAREXEL
International Corporation (NASDAQ: PRXL), a leading global
biopharmaceutical services provider, today launched the next
generation of its Perceptive MyTrials® platform with
advanced analytics capabilities. With the Perceptive MyTrials
Analytics solution, clinical trial sponsors can now use a
mobile-enabled, single entry-point to access predictive data
analytics for multiple studies simultaneously. The solution
offers real-time and aggregated analytics allowing sponsors and
PAREXEL® clinical research professionals to detect key
signals and trends. The Perceptive MyTrials Analytics
solution also offers cross-sponsor viewing options for clients who
need to evaluate data from multiple sponsors.
"As clinical studies become more complex, there is a growing
need for real-time and standardized data and analytics from
multiple studies," said Xavier Flinois, President, PAREXEL
Informatics. "Using the enhanced tools available with the
Perceptive MyTrials Analytics solution, our clients can visualize
trends across studies, garner reliable intelligence, and
confidently make data-driven business decisions. This information
will ultimately help reduce risk, increase clinical trial
efficiency, and speed time to market for our clients and for
patients."
Developed by PAREXEL Informatics, the Perceptive
MyTrials® platform provides an integrated suite of
applications for managing clinical trials. Perceptive
MyTrials Analytics offers enhanced analytics capabilities and
cross-study business intelligence from within the Perceptive
MyTrials platform.
Flinois added, "At PAREXEL, our mission is to bring science to
the real world by simplifying a client's journey at every
step. Perceptive MyTrials Analytics is another example of the
integrated solutions we are developing that incorporate optimized
study management processes that leverage mobile and analytics as
part of our broader 'SMAC' [social media, mobile, analytics, and
cloud] technology approach."
Perceptive MyTrials® Analytics is available directly
as part of PAREXEL clinical research services or via the
Perceptive® Partner Program.
About PAREXEL International
PAREXEL International Corporation is a leading global
biopharmaceutical services organization, providing a broad range of
expertise-based contract research, consulting, medical
communications, and technology solutions and services to the
worldwide pharmaceutical, biotechnology and medical device
industries. Committed to providing solutions that expedite
time-to-market and peak-market penetration, PAREXEL has developed
significant expertise across the development and commercialization
continuum, from drug development and regulatory consulting to
clinical pharmacology, clinical trials management, medical
education and reimbursement. PAREXEL Informatics, Inc. provides
advanced technology solutions, including medical imaging, to
facilitate the clinical development process. Headquartered near
Boston, Massachusetts, PAREXEL
operates in 80 locations in 51 countries around the world, and had
approximately 17,440 employees in the third quarter. For more
information about PAREXEL International visit www.PAREXEL.com.
PAREXEL, PAREXEL Informatics, Perceptive, and Perceptive
MyTrials are trademarks or registered trademarks of PAREXEL
International Corporation or its affiliates. All other
trademarks are the property of their respective owners.
This release contains "forward-looking" statements regarding
future results and events, including, without limitation,
statements regarding expected financial results, future growth and
customer demand. For this purpose, any statements
contained herein that are not statements of historical fact may be
deemed forward-looking statements. Without limiting the
foregoing, the words "believes," "anticipates," "plans," "expects,"
"intends," "appears," "estimates," "projects," "will," "would,"
"could," "should," "targets," and similar expressions are
also intended to identify forward-looking statements. The
forward-looking statements in this release involve a number of
risks and uncertainties. The Company's actual future results
may differ materially from the results discussed in the
forward-looking statements contained in this release.
Important factors that might cause such a difference include, but
are not limited to, risks associated with: actual operating
performance; actual expense savings and other operating
improvements resulting from restructurings; the loss, modification,
or delay of contracts which would, among other things, adversely
impact the Company's recognition of revenue included in backlog;
the Company's dependence on certain industries and clients; the
Company's ability to win new business, manage growth and costs, and
attract and retain employees; the Company's ability to complete
additional acquisitions, and to integrate newly acquired businesses
including the acquisitions of ClinIntel Limited and Quantum
Solutions India, or enter into new lines of business; the impact on
the Company's business of government regulation of the drug,
medical device and biotechnology industry; consolidation within the
pharmaceutical industry and competition within the
biopharmaceutical services industry; the potential for significant
liability to clients and third parties; the potential adverse
impact of health care reform; and the effects of foreign currency
exchange rate fluctuations and other international economic,
political, and other risks. Such factors and others are
discussed more fully in the section entitled "Risk Factors" of the
Company's Quarterly Report on Form 10-Q for the quarter ended
March 31, 2015 as filed with the
Securities and Exchange Commission on May 1,
2015, which "Risk Factors" discussion is incorporated by
reference in this press release. The Company specifically
disclaims any obligation to update these forward-looking statements
in the future. These forward-looking statements should not be
relied upon as representing the Company's estimates or views as of
any date subsequent to the date of this press release.
Contacts:
Diana Martin,
PAREXEL International
Tel: +1 781-434-5516
Email: Diana.Martin@PAREXEL.com
Cristi Barnett, PAREXEL
International
Tel.: +1 781-434-4019
Email: Cristi.Barnett@PAREXEL.com
Matthew Briggs, PAN
Communications
Tel: +1 617-502-4300
Email: PAREXEL@pancomm.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/parexel-launches-next-generation-analytics-capabilities-within-perceptive-mytrials-platform-300114647.html
SOURCE PAREXEL International Corporation